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ABSTRACT
Objective: Our aim in this study was to examine the
competing interest policies and procedures of
organisations who develop and maintain patient
decision aids.
Design: Descriptive and thematic analysis of data
collected from a cross-sectional survey of patient
decision aid developer’s competing interest policies
and disclosure forms.
Results: We contacted 25 organisations likely to meet
the inclusion criteria. 12 eligible organisations provided
data. 11 organisations did not reply and 2 declined to
participate. Most patient decision aid developers
recognise the need to consider the issue of competing
interests. Assessment processes vary widely and, for
the most part, are insufficiently robust to minimise the
risk of competing interests. Only half of the 12
organisations had competing interest policies. Some
considered disclosure to be sufficient, while others
imposed differing levels of exclusion.
Conclusions: Patient decision aid developers do not
have a consistent approach to managing competing
interests. Some have developed policies and
procedures, while others pay no attention to the issue.
As is the case for clinical practice guidelines,
increasing attention will need to be given to how the
competing interests of contributors of evidence-based
publications may influence materials, especially if they
are designed for patient use.
INTRODUCTION
Identifying and managing financial and intel-
lectual competing interests are increasingly
recognised as a vital step when producing
clinical practice guidelines for profes-
sionals.1 2 When similar information is devel-
oped for patients, such as in the form of a
decision aid, it becomes even more import-
ant to minimise competing interests.
Clinical guideline recommendations are
designed to influence clinical practice by dis-
seminating the results of a rigorous analysis
of scientific evidence. It is therefore critical
to ensure that their messages are not biased
by other interests. However, over many years,
significant concerns have been raised
about the financial relationships between
guideline panel experts and commercial
entities, typically pharmaceutical companies,3
and doubts have been voiced about the
validity of recommendations. For example,
Cosgrove4 reported that all members of the
American Psychiatric Association’s Practice
Guideline for the Treatment of Patients with
Major Depressive Disorder had financial ties
to the pharmaceutical industry. The response
to these concerns in the domain of guide-
lines has been the development of strategies
to better manage such relationships and to
make them more transparent.2 5
Working to increase transparency and
perhaps minimise competing interests by
excluding contribution has even more rele-
vance when developing information sources
for patients, given they are arguably more
vulnerable to bias than health professionals.
There is a wide range of patient-facing infor-
mation being produced, which falls into mul-
tiple types of knowledge tools.6 One category
—patient decision aids—has been the
subject of substantial research scrutiny and
support over the past two decades. A system-
atic review of 115 trials has shown that they
increase patient knowledge, accuracy of risk
perception and, in some situations, signifi-
cantly influence decisions about tests and
treatments.7 In short, they have significant
influence. In consequence, the International
Strengths and limitations of this study
▪ Multiple sources were used to identify patient
decision aid organisations.
▪ Independent dual data extraction and coding.
▪ Some patient decision aid organisations were
unwilling to provide data.
▪ Possible non-identification of some patient deci-
sion aid organisations.
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Patient Decision Aids Standards Collaboration has
argued that patient decision aids should be as free as
possible of competing interests.8
In 2013, Barry et al9 updated the International Patient
Decision Aids Standards Collaboration criteria and sug-
gested a more stringent approach to the disclosure of
competing interests in patient decision aid development.
However, it is unclear whether patient decision aid
developers have addressed the issue of how competing
interests are identified and managed. Pioneers in this
field were, for the most part, working in academic set-
tings, but as interest has grown and a market has
emerged, larger organisations—both commercial and
non-profit—have appeared. These organisations may
accept funding from multiple sources, and recruit a
range of contributors, clinical experts, patient advocates
and others. They may also use existing evidence sources
to provide up-to-date content. The need for transpar-
ency is clear. As with clinical practice guideline produc-
tion, individual-level and institutional-level conflicts of
interest should be disclosed and managed. Our aim in
this study was to examine the competing interest policies
and procedures of organisations who develop and main-
tain patient decision aids.
METHODS
Participants
We identified organisations that were known to produce
patient decision aids by using inventories, publications,
academic networks, email groups and conference pro-
ceedings. Organisations were invited to participate in
the study if they: (1) had produced five or more patient-
facing decision aids that were publicly or commercially
available as of June 2015, and (2) had actively main-
tained and updated those tools.
For the purpose of this study, we adapted the defin-
ition of patient decision aids used in the Cochrane sys-
tematic review of patient decision aids.7 Eligible
organisations were those that produced interventions
that: (1) help patients make deliberate informed health-
care decisions; (2) explicitly state the decision to be con-
sidered; (3) provide balanced evidence-based
information about available options, describing their
associated benefits, harms and probabilities; and (4)
support patients to recognise and clarify preferences.
Data collection
A standard email was sent to organisations identified as
possibly eligible requesting a copy of their competing
interest policy and declaration of interest form(s), as
well as any other documents used to manage the rele-
vant competing interests of their contributors, writers or
experts, and those involved in the evidence synthesis
process (see online supplementary material). We also
requested data about the number and format of the
organisation’s patient decision aids. If we received
incomplete or unclear information, additional inquiries
were made. Reminders were sent at 1 and 2 weeks, and
non-responses were documented.
After piloting a data extraction form, two researchers
(M-AD and MD) independently tabulated data about
the organisation’s name, location, number of active
patient decision aids available, patient decision aid
access (free or commercial), and patient decision aid
type (eg, paper, web or video-based, or other). Data
were summarised regarding each organisation’s compet-
ing interest approach: scope, principles, applicability,
coverage and date of implementation.
Data analysis
To identify themes in the data, all documented com-
peting interest policies received were examined using
qualitative methods, specifically thematic analysis.
Undocumented approaches to managing competing
interests mentioned in verbal or email communications
were not included in the thematic analysis. MD and AB
independently reviewed the extracted data and devel-
oped a preliminary codebook, using three of the docu-
ments received. Discrepancies in coding were discussed
with M-AD until a definitive codebook was agreed, and
applied by MD and AB to all policy documents using
ATLAS.ti V.1.0.34. Inconsistent coding was resolved by
consultation with M-AD. Codes across organisations were
compared. Each organisation was asked to verify our
interpretation of data in relation to existence of a docu-
mented policy, disclosure form, their approach to exclu-
sion where competing interests were identified, their
active number of patient decision aids and whether the
tools were available publically or commercially; factual
errors were addressed. Authors who were also members
of the Option Grid Collaborative did not extract, code
or analyse data from that organisation. Option Grid
Collaborative data were handled by UP and MD.
RESULTS
Patient decision aid organisations
We contacted 25 organisations which we considered
likely to meet the preset inclusion criteria (see figure 1).
Twelve eligible organisations provided data (table 1).
Eleven organisations did not reply and two declined to
participate (see table 1 footnote). We do not know
whether the non-responders were eligible, and we are
unable to report data from those who declined participa-
tion. Eight of the 12 participating organisations were
based in the USA, and one each in Australia, Canada,
Germany and the Netherlands. The number of available
decision aids, their format and mode of access varied
across organisations. As of June 2015, the three largest
developers were Healthwise, the Agency for Healthcare
Research and Quality, and Health Dialog, with 180, 51
and 38 available patient decision aids, respectively.
Other developers had smaller numbers of available
tools. The majority of organisations were not-for-profit
organisations (n=9). Most decision aids were web-based,
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often with print versions available. Eight out of 12 organi-
sations allowed free access to the tools. Four organisations
required payment or licences, although two of these orga-
nisations allowed limited free access to some tools.
Summary of competing interest approaches
Organisations producing patient decision aids do not
have a consistent approach when dealing with compet-
ing interests. Some have written policies, others use an
informal approach, and some collect information about
competing interests without having a clear policy on
how to manage identified conflicts (table 2). Six of the
12 participating organisations (Agency for Healthcare
Research and Quality, Cincinnati Children’s Hospital
Medical Center (CCHMC), Health Dialog, Healthwise,
Option Grid Collaborative, and Sydney School of Public
Health) sent us their written competing interests policy.
Two of the other six organisations reported following
undocumented competing interest principles (Mayo Clinic
and University Medical Center Hamburg), and another
used criteria specified by the International Patient
Decision Aids Standards Collaboration (Ottawa Hospital
Research Institute). Two of the three for-profit organisa-
tions (Emmi Solutions and WiserCare) did not have a
documented competing interest policy. Five of the 12
decision aid organisations had a rigorous approach to
disclosing competing interests, defined as having a
written policy, a disclosure of competing interests form,
and a process of deciding whether or not to exclude
contributors with competing interest. Six organisations
barred contributors who had competing interests from
contributing to development processes (Agency for
Healthcare Research and Quality, CCHMC, Healthwise,
Option Grid Collaborative, Sydney School of Public
Health, and Mayo Clinic), all with exemptions possible,
six did not. Eight of the 12 organisations used forms to
collect information about competing interests. Of the
other four organisations, two reported asking for infor-
mal disclosures. Four organisations did not have a
formal method of identifying competing interest and
did not have a documented policy. Five organisations
disclosed competing interests on their patient decision
aids, directly (Emmi Solutions, Ottawa Hospital
Research Institute, and PATIENT+) or by using
Figure 1 Flowchart of organisations from identification to inclusion in analysis.
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associated web links (Agency for Healthcare Research
and Quality and Healthwise).
Thematic analysis of available competing interest policies
and forms
Our thematic analysis included six policies and two
interest disclosure forms (from organisations who had
no documented policies), see table 2. We identified the
following four main themes in the data: timeframe,
application of policy, interests included or exempted,
and management of disclosures.
Timeframe
Six organisations (four policies and two disclosure
forms) mentioned timeframes for disclosure relevance.
Healthwise considered past competing interests only,
defined as those ‘received in the last year’. Health
Dialog considered current competing interests only.
Four organisations (Agency for Healthcare Research
Quality, CCHMC, Option Grid Collaborative and
PATIENT+) considered both past and future interests.
Of those who specified that past interests must be
declared, the applicable time period ranged from 12 to
36 months. We assume ‘future interests’ to imply current
interests at time of disclosure. Similar inconsistent
approaches were found regarding the timing at which
information about interests was collected—whether at
the start of development, or on a regular basis. Only
four organisations requested proactive reporting of any
changes in disclosures if new competing interests arose.
Application of policy
All six documents were clear that the policy applied to
contributors, and included family members, but defini-
tions varied. The Agency for Healthcare Research and
Quality and the Option Grid Collaborative included
spouse, domestic partner and dependent children.
Other organisations (CCHMC, Health Dialog and
Healthwise) did not provide details. The Sydney School
of Public Health’s policy was the most extensive, includ-
ing spouse, de facto partner, sexual partner, immediate
family, close friend, a financial dependent or business
partner.
Interests included and exempted
All six policies and one disclosure form mentioned the
relevance of financial interests and this was defined in
detail by four policies and one disclosure form.
Healthwise and the Option Grid Collaborative required
disclosure of financial interests, irrespective of the
amount. The Agency for Healthcare Research and
Quality described multiple disclosure thresholds,
depending on the nature of an individual’s involvement.
Five organisations (Agency for Healthcare Research and
Quality, CCHMC, Health Dialog, PATIENT+, and the
Sydney School of Public Health) also required the dis-
closure of non-financial interests, such as potential intel-
lectual interests or career advancement.
Three policies and one disclosure form indicated
which types of interests did not require disclosure. The
Agency for Healthcare Research and Quality does not
Table 1 Patient decision aid organisations* (as of June 2015)
Organisation Country
Decision
aids Format Access
Profit
status
Agency for Healthcare
Research and Quality
USA 51 Web-based with PDF available Free NP
Cincinnati Children’s Hospital
Medical Center
USA 5 Paper-based, some PDFs
available online
Free NP
Emmi Solutions USA 15+ Video-based animation Commercial FP
Health Dialog USA 38 Website, video, and/or booklet Commercial† FP
Healthwise USA 180 Web-based with PDF available Commercial† NP
Mayo Clinic USA 5 Electronic interactive tool,
paper, video
Free NP
Ottawa Hospital Research
Institute
Canada 16 Web-based with PDF available Free NP
Option Grid Collaborative USA 37 Electronic interactive tool,
paper
Free NP
PATIENT+ The
Netherlands
10 Web-based, video Free NP
University Medical Center
Hamburg
Germany 9 Electronic interactive tool,
paper
Free NP
Sydney School of Public Health Australia 6 Website, PDF and audio Free NP
WiserCare USA 10 Web-based Commercial FP
*Two of the following patient decision aid organisations declined participation and 11 did not reply to correspondence: British Medical Journal
(UK), Choosing Wisely (USA), Decision Box, University of Laval (Canada); ‘Having a Baby’, University of Queensland (Australia), NHS Right
Care (UK), The MedicalGuide (USA), Midwifery Information and Resource Service (UK), Queen Mary University (UK), Visualizing Health
(USA), Vitality Group (USA), Wellvie (USA), Wiser Together (USA).
†Some public access granted.
FP, for profit; NP, not-for-profit.
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Table 2 Overview of organisational approaches to managing competing interests
Documented policy and disclosure forms
Disclosure forms,
no policy No policy, No disclosure forms
AHRQ CCHMC
Health
Dialog Healthwise
Option
Grid Sydney
PATIENT
+ Ottawa Emmi Mayo WiserCare Hamburg
Applies to contributor and family
members
✓ ✓* ✓ ✓ ✓ ✓
Applies to financial interests only ✓ ✓
Applies beyond financial interests ✓ ✓ ✓ ✓ ✓
Full financial disclosure ✓† ✓ ✓ ✓
Past interest disclosure ✓
Current interest disclosure ✓
Past and future interest disclosure ✓ ✓ ✓ ✓
Restrictions placed on contributors
with competing interests
✓ ✓ ✓
Exclusion of contributors with
competing interests
✓ ✓ ✓ ✓ ✓ ✓
Documented process for evaluating
disclosures
✓ ✓ ✓ ✓ ✓
Documented policy exemptions ✓ ✓ ✓ ✓ ✓
Competing interest principles
followed
✓‡ ✓ ✓
Request informal disclosures ✓ ✓
Disclosure made on decision aid ✓§ ✓§ ✓ ✓ ✓
*Applies to lead editors only.
†Threshold for financial disclosure is role dependent.
‡Follow IPDAS.
§Web link to disclosure provided on decision aid.
AHRQ, Agency for Healthcare Research and Quality; CCHMC, Cincinnati Children’s Hospital Medical Center; Emmi, Emmi Solutions; IPDAS, International Patient Decision Aids Standards;
Mayo, Mayo Clinic; Ottawa, Ottawa Hospital Research Institute; Option Grid, Option Grid Collaborative; Hamburg, University Medical Center Hamburg; Sydney, Sydney School of Public Health.
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require disclosure of service on advisory committees or
review panels for public/non-profit entities, equity inter-
ests in a single entity below 5%, ownership in an institu-
tion if the institution is an applicant under the Small
Business Innovation Research programme, income from
seminars/lectures/teaching engagements for a public or
non-profit entity, or for mutual or retirement funds.
CCHMC does not require disclosure of salary, royalties
or other remuneration received directly from CCHMC,
equity interests in a single entity below 5%, royalties for
publishing scholarly works or other writings, or of
mutual or retirement funds. Healthwise also does not
require disclosure of mutual or retirement funds.
PATIENT+ does not require funding from public
funding sources to be disclosed.
Management of disclosures
All organisations who had published a policy also had a
method for collecting information about competing
interests but less clarity about who would evaluate and
act on the disclosures. Policies varied widely in terms of
how to manage the disclosure of competing interests.
None of the policies absolutely excluded individuals if
competing interests were disclosed; all had some form of
exemption. Five documented policies recommended,
but did not require, excluding contributions from indivi-
duals with competing interests. Three of these five pol-
icies suggested that individuals should have limited roles
in development or editorial processes. No policies for-
mally required disclosed competing interests to be pub-
lished directly on patient decision aids, although three
organisations did so (Emmi Solutions, Ottawa Hospital
Research Institute and PATIENT+).
DISCUSSION
Main findings
Most, but not all, patient decision aid organisations rec-
ognise the need to consider the issue of competing
interests. Nevertheless, processes vary widely and, for the
most part, are insufficiently robust to minimise the risk
that the information contained in these knowledge tools
may be biased. At the time of analysis, we identified 12
organisations who had five or more tools in their inven-
tory, indicating that relatively few number of organisa-
tions work in this field. Only half of these organisations
had a documented competing interest policy, demon-
strating a lack of attention to an area that is causing
increasing concern for those summarising evidence for
patient and professional consumption. The organisa-
tions who had developed policies varied widely in the
restrictions imposed on those who declared competing
interests, and none required competing interest disclosure
to be published on patient decision aids. Some consid-
ered declarations to be sufficient, others imposed differ-
ing levels of exclusion from content development. No
policies definitively prohibited the involvement of indivi-
duals with competing interests. The management of
non-financial competing interests—for example, sur-
geons benefitting from a general uptake of surgical pro-
cedures in their discipline is a matter of ongoing debate.
Some guideline producers, for example, the Institute of
Medicine and the National Institute for Health and
Care Excellence are addressing this challenge by requir-
ing higher standards from those who have ultimate edi-
torial power, such as chairs of guideline panels.
Study strengths and weaknesses
We used multiple sources to identify patient decision aid
organisations, and subsequently limited our focus to
those who had developed and were actively maintaining
five or more tools. These organisations therefore repre-
sent the most active organisations committed to the
development of evidence-based knowledge tools de-
signed to support patient-facing decision-making pro-
cesses. Other organisations may exist that develop fewer
tools but it is unlikely that they have significant numbers
of patients accessing their products. The included orga-
nisations are likely to be aware of criteria published by
the International Patient Decision Aids Standards
Collaboration, which include recent recommendations
regarding competing interest disclosure.8 Some organi-
sations declined participation, and although we are con-
fident that we identified the most relevant organisations,
it is possible that other organisations exist. We achieved
a rigorous analysis by adopting descriptive and qualita-
tive methods, and independent dual data extraction and
coding. Data provided by the Option Grid Collaborative
were not extracted, coded or analysed by members of
that organisation (AB, M-AD or GE).
Comparison with other studies
Previous studies have not examined the policies of
organisations who develop and maintain patient deci-
sion aids, although the International Patient Decision
Aids Standards Collaboration has consistently made
recommendations regarding competing interests.8
Organisations in the USA at state and national levels are
currently considering whether or not patient decision
aids should be subjected to certification, as called for in
section 3506 of the Patient Protection and Affordable
Care Act.10 11 At the same time, the topic of competing
interests among members of clinical guideline panels
has also been under increasing scrutiny,12–14 with recent
calls to minimise or avoid financial and professional con-
flicts during the development of guidelines.14 The
common thread seems to be concern about trustworthy
summary of scientific evidence, whether intended for
professionals or patients.
In a systematic literature search of articles from 2001
to 2011, Barry et al9 found no articles that examined the
impact of COI disclosure in patient decision aids on
reducing bias in decision-making, showing a lack of
attention to the topic in the scientific community. Their
recommendations focused on transparent reporting of
funding sources and whether organisations or
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individuals stood to gain or lose by the choices made by
patients. While these recommendations strengthen pre-
vious recommendations made by the International
Patient Decision Aids Standards Collaboration, they are
less comprehensive than policies used by some organisa-
tions included in this analysis.
Practice implications
This study illustrates the wide variation in the attention
given to competing interests when developing informa-
tion materials called patient decision aids. The most
rigorous approach was illustrated by the policy adopted
by the Agency for Healthcare Research and Quality,
while some organisations paid no attention to the issue,
or assumed that informal processes were sufficient pro-
tection. Although the International Patient Decision
Aids Standards Collaboration has produced ‘quality’ cri-
teria, patient decision aid producers do not seem to
have adopted the need to address the issue of compet-
ing interests, and to systematically disclose this informa-
tion on decision aids or supporting documents. Indeed,
some organisations indicated that this study had
prompted them to pay more attention to this issue and
review or develop policies. As observed in the domain of
clinical practice guidelines, increasing attention needs to
be given to how the competing interests of contributors,
authors and editors will influence the process of evi-
dence synthesis, especially for patient facing-materials,
and how they need to be disclosed, reduced and
managed—and, in certain cases, eliminated.
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